Cardiovascular diseases (CVDs) are the leading cause of non-communicable disease (NCD) deaths in India, accounting for nearly ...

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...

NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode ...

When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first cardiovascular event, new data show.

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

Factors linked to heart problems, such as high blood pressure, diabetes and bad cholesterol levels, can start years, ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...